Liberopoulos, Evangelos

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

The effects of orlistat and fenofibrate, alone or in combination, on high‐density lipoprotein subfractions and pre‐beta1‐HDL levels in obese patients with metabolic syndrome

Filippatos, T. D., Liberopoulos, E. N., Kostapanos, M., Gazi, I. F., Papavasiliou, E. C., Kiortsis, D. N., Tselepis, A. D., & Elisaf, M. S. (2008) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentLipoproteins and Cardiovascular Health

Cited by 51